Call of Duty at the Frontier of Research: Normative Epistemology for High-Risk/High-Gain Studies of Deep Brain Stimulation.

Research participants are entitled to many rights that may easily come into conflict. The most important ones are that researchers respect their autonomy as persons and act on the principles of beneficence, nonmaleficence, and justice. Since 2014, research subjects from numerous states in the United States of America also have a legal "right to try" that allows them, under certain circumstances, to receive experimental (i.e., preliminarily tested) interventions, including medical devices, before official approval from the United States Food and Drug Administration. In the context of experimental interventions, such as deep brain stimulation (DBS) for Alzheimer's disease, this article argues that research participants ought never to have a legal "right to try" without a corresponding "right to be sure." The latter refers to external epistemic justification construed in terms of reliance on reliable evidence. This article demonstrates that the mere complexity of intervention ensembles, as in the case of DBS for Alzheimer's disease which serves as a paradigm example, illustrate how unanswered and/or unasked open questions give rise to a "combinatorial explosion" of uncertainties that require epistemic responses that no single research team alone is likely able to provide. From this assessment, several epistemic asymmetrical relations between researchers and participants are developed. By elucidating these epistemic asymmetries, this article unravels the reasons why open science, transparent exhaustive data reporting, preregistration, and continued constant critical appraisal via pre- and postpublication peer review are not scientific virtues of moral excellence but rather ordinary obligations of the scientific work routine required to increase reliability and strength of evidence.

[1]  M. McCormick Ethics of Belief , 2020, International Encyclopedia of Ethics.

[2]  S. Müller,et al.  Opening the debate on deep brain stimulation for Alzheimer disease – a critical evaluation of rationale, shortcomings, and ethical justification , 2018, BMC Medical Ethics.

[3]  S. John Epistemic trust and the ethics of science communication: against transparency, openness, sincerity and honesty , 2018 .

[4]  T. Insel Join the disruptors of health science , 2017, Nature.

[5]  M. Johansson,et al.  Challenges to Informed Consent in First-In-Human Trials Involving Novel Treatments: A Case Study of Parkinson’s Disease , 2017, Journal of Parkinson's disease.

[6]  S. Mueller,et al.  P 137 An ethical perspective on deep brain stimulation as an investigational treatment for Alzheimer’s disease , 2017, Clinical Neurophysiology.

[7]  Gerd Gigerenzer,et al.  Can facts trump unconditional trust? Evidence-based information halves the influence of physicians’ non-evidence-based cancer screening recommendations , 2017, PloS one.

[8]  F. Gilbert,et al.  Currents of memory: recent progress, translational challenges, and ethical considerations in fornix deep brain stimulation trials for Alzheimer's disease , 2017, Neurobiology of Aging.

[9]  Sanford C. Goldberg Should have known , 2017, Synthese.

[10]  J. Fins In Reply: Commentary: Deep Brain Stimulation as Clinical Innovation: An Ethical and Organizational Framework to Sustain Deliberations About Psychiatric Deep Brain Stimulation. , 2017, Neurosurgery.

[11]  Jeannie-Marie S. Leoutsakos,et al.  A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer’s Disease , 2016, Journal of Alzheimer's disease : JAD.

[12]  Brian A. Nosek,et al.  How open science helps researchers succeed , 2016, eLife.

[13]  E. Racine,et al.  Deep Brain Stimulation as Clinical Innovation: An Ethical and Organizational Framework to Sustain Deliberations About Psychiatric Deep Brain Stimulation. , 2016, Neurosurgery.

[14]  N. Eyal How to keep high-risk studies ethical: classifying candidate solutions , 2016, Journal of Medical Ethics.

[15]  Genserik Reniers,et al.  On the assessment of uncertainty in risk diagrams , 2016 .

[16]  Jelte M. Wicherts,et al.  Peer Review Quality and Transparency of the Peer-Review Process in Open Access and Subscription Journals , 2016, PloS one.

[17]  Valerie C. Henderson,et al.  Assessing risk/benefit for trials using preclinical evidence: a proposal , 2015, Journal of Medical Ethics.

[18]  S. Goodman,et al.  Meta-research: Evaluation and Improvement of Research Methods and Practices , 2015, PLoS biology.

[19]  Brian A. Nosek,et al.  Promoting an open research culture , 2015, Science.

[20]  J. Kimmelman,et al.  The structure of clinical translation: efficiency, information, and ethics. , 2015, The Hastings Center report.

[21]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[22]  K. Zilles,et al.  Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer’s dementia , 2014, Molecular Psychiatry.

[23]  Ulrich Dirnagl,et al.  Distinguishing between Exploratory and Confirmatory Preclinical Research Will Improve Translation , 2014, PLoS biology.

[24]  J. Kimmelman,et al.  A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries , 2012, Trials.

[25]  D. Howells,et al.  Can Animal Models of Disease Reliably Inform Human Studies? , 2010, PLoS medicine.

[26]  Iveta Simera,et al.  Helping editors, peer reviewers and authors improve the clarity, completeness and transparency of reporting health research , 2008, BMC medicine.

[27]  C. Grady,et al.  What makes clinical research ethical? , 2000, JAMA.

[28]  M. Knopp,et al.  Deep Brain Stimulation of Frontal Lobe Networks to Treat Alzheimer's Disease. , 2018, Journal of Alzheimer's disease : JAD.

[29]  C. Grady,et al.  Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. , 2003, IRB.